greeksoup/ stock research
Stock research / United States / Funds / First Light Asset Management, LLC

First Light Asset Management, LLC

CIK 1600004 · latest 13F filed 14 August 2026 · Read the filing on EDGAR

First Light Asset Management, LLC reported 31 US-listed holdings worth $1.65 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Neogenomics Inc. (10.9%), Si-Bone Inc. (8.1%) and Axogen Inc. (7.7%). Against the quarter before, it opened 2 positions, added to 17, trimmed 12 and sold out of 6.

Reported holdings$1.65B+47.4% on Q1 2026
Positions31-4 on Q1 2026
The largest ten60.7%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Where the money is
Added toTrimmed
NEO10.9%SIBN8.1%AXGN7.7%APGE7.5%PVLA7.2%TWST4.6%ELVN4.2%GH4.0%MASS3.3%AMLX3.3%WGS3.3%SLP3.1%TNDM3.1%CRNX17 more26.7%

The 14 largest of its 31 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q3 2024: $1.20 billion in 38 positions$1.20BQ3 24Q4 2024: $1.05 billion in 36 positions$1.05BQ4 24Q1 2025: $875.7 million in 37 positions$876MQ1 25Q2 2025: $771.3 million in 38 positions$771MQ2 25Q3 2025: $1.06 billion in 41 positions$1.06BQ3 25Q4 2025: $1.31 billion in 33 positions$1.31BQ4 25Q1 2026: $1.12 billion in 35 positions$1.12BQ1 26Q2 2026: $1.65 billion in 31 positions$1.65BQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What it did on the quarter

Opened 2Added 17Trimmed 12Sold out 6
Opened: 2Added: 17Trimmed: 12Sold out: 6

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Opened 2

  1. Trevi Therapeutics Inc. TRVI$39.1 million
  2. Tactile Sys Technology Inc. TCMD$13.8 million

Added to 17

  1. Enliven Therapeutics Inc. ELVN+1.2 million shares · +574%
  2. Apogee Therapeutics Inc. APGE+353,605 shares · +61%
  3. Si-Bone Inc. SIBN+2.8 million shares · +52%
  4. Neogenomics Inc. NEO+2.5 million shares · +26%
  5. Genedx Holdings Corp. WGS+540,996 shares · +223%
  6. Tandem Diabetes Care Inc. TNDM+2.1 million shares · +157%
  7. Guardant Health Inc. GH+161,287 shares · +58%
  8. Vaxcyte Inc. PCVX+203,373 shares · +143%

and 9 more in the table below

Trimmed 12

  1. Axogen Inc. AXGN-1.3 million shares · -31%
  2. Palvella Therapeutics Inc. Ne PVLA-208,857 shares · -21%
  3. Twist Bioscience Corp. TWST-150,915 shares · -17%
  4. Establishment Labs Holdings In ESTA-61,161 shares · -20%
  5. Atricure Inc. ATRC-161,683 shares · -22%
  6. Amylyx Pharmaceuticals Inc. AMLX-167,389 shares · -5%
  7. Koru Medical Systems Inc. KRMD-380,478 shares · -10%
  8. Omnicell, Inc. OMCL-37,522 shares · -8%

and 4 more in the table below

Sold out of 6

  1. Centessa Pharmaceuticals PLC CNTA$62.0 million last quarter
  2. Wave Life Sciences Ltd WVE$13.4 million last quarter
  3. Vera Therapeutics Inc. VERA$12.6 million last quarter
  4. Mimedx Group Inc. MDXG$11.2 million last quarter
  5. Spyglass Pharma Inc. SGP$9.7 million last quarter
  6. Organogenesis Hldgs Inc. ORGO$8.3 million last quarter

What it holds

CompanySharesValueOf its bookChange in shares
Neogenomics Inc. NEO12,279,523$179.2 million10.89%+2,549,545
Si-Bone Inc. SIBN8,127,985$132.6 million8.06%+2,774,795
Axogen Inc. AXGN2,748,361$126.9 million7.72%-1,254,407
Apogee Therapeutics Inc. APGE930,289$123.5 million7.50%+353,605
Palvella Therapeutics Inc. Ne PVLA771,901$118.0 million7.17%-208,857
Twist Bioscience Corp. TWST727,933$74.9 million4.55%-150,915
Enliven Therapeutics Inc. ELVN1,360,750$69.1 million4.20%+1,158,883
Guardant Health Inc. GH441,586$66.3 million4.03%+161,287
908 Devices Inc. MASS6,282,804$54.7 million3.32%+210,241
Amylyx Pharmaceuticals Inc. AMLX3,023,256$54.3 million3.30%-167,389
Genedx Holdings Corp. WGS783,923$53.8 million3.27%+540,996
Simulations Plus Inc. SLP2,792,677$51.1 million3.11%+159,854
Tandem Diabetes Care Inc. TNDM3,383,553$51.1 million3.10%+2,068,838
Crinetics Pharmaceuticals in CRNX1,360,866$50.9 million3.10%+271,196
Neuropace Inc. NPCE2,861,167$45.5 million2.76%+401,201
Edgewise Therapeutics Inc. EWTX1,095,171$44.5 million2.70%+93,325
Anaptysbio Inc. ANAB582,004$39.3 million2.39%+16,573
Trevi Therapeutics Inc. TRVI2,097,215$39.1 million2.38%new
Septerna Inc. SEPN963,260$32.3 million1.96%+230,400
Trisalus Life Sciences Inc. TLSI6,552,491$29.8 million1.81%+1,485,664
Tectonic Therapeutic Inc. TECX800,726$27.5 million1.67%+152,983
Health Catalyst Inc. HCAT12,810,861$25.5 million1.55%-67,839
Butterfly Network Inc. BFLY2,642,404$22.2 million1.35%-17,763
Establishment Labs Holdings In ESTA246,577$21.2 million1.29%-61,161
Vaxcyte Inc. PCVX345,157$20.1 million1.22%+203,373
Irhythm Technologies Inc. IRTC167,092$19.9 million1.21%-1,024
Omnicell, Inc. OMCL452,324$18.8 million1.14%-37,522
Atricure Inc. ATRC567,838$15.9 million0.97%-161,683
Koru Medical Systems Inc. KRMD3,387,902$14.2 million0.86%-380,478
Tactile Sys Technology Inc. TCMD462,562$13.8 million0.84%new
Rhythm Pharmaceuticals Inc. RYTM85,765$9.5 million0.58%-1,416
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before; the 6 it sold out of are in the box above.